<DOC>
	<DOCNO>NCT01564836</DOCNO>
	<brief_summary>This prospective study perform identify safer concrete indicator successful discontinuation explore contribute factor sustain undetectable transcript</brief_summary>
	<brief_title>Discontinuation Study Imatinib Adult CP CML Patients Who Have Complete Molecular Response Imatinib</brief_title>
	<detailed_description>Imatinib ( IM ) treatment standard care chronic phase ( CP ) chronic myeloid leukemia ( CML ) approximately 50 % CP CML patient receive IM treatment achieve complete molecular response ( CMR ) 6-7 year . ( Hochhaus A et al . Leukemia 2009 ; 23:1054-1061 , Hughes et al . Blood 2008 ; 112:334 ) The recent data study aim ass whether IM discontinue patient CMR last least 2 year show probability persistent CMR 12 month 41 % , suggest IM safely discontinue , least patient sustain CMR . ( Mahon et al . Lancet Oncol 2010 ; 11:1029-1035 ) However , define whether discontinuation IM treatment safely employ , validation much longer follow-up need . Aims This prospective study perform identify safer concrete indicator successful discontinuation explore contribute factor sustain undetectable transcript . Primary Objective : - To evaluate probability persistent undetectable molecular residual disease ( UMRD ) MR4.5 12 month discontinuation - To measure duration persistent UMRD MR4.5 discontinuation - To identify contribute factor sustain undetectable transcript Secondary Objective : - To evaluate probability major molecular response ( MMR ) loss - To evaluate time take lose MMR 12 month discontinuation - In patient loss MMR , probability re-achieving MMR/MR4.5 - To measure time take re-achieve MMR/MR4.5 IM resumption - To identify contribute factor sustain re-achieve MMR/MR4.5 Trial Design This prospective , multicenter , non-randomised IM discontinuation study . Response Evaluation After discontinuation , molecular response monitor use RQ-PCR assay every month 6 month follow-up , every 2 month 12 month follow-up , every 3 month thereafter . The loss MMR , MR4.5 , UMRD define 2 consecutive assessment . If loss MMR occur , IM treatment re-introduced . Written inform consent obtain patient</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Adult ( â‰¥ 18 yearsold ) Ph+ CP CML patient treat IM 3 year sustain MR4.5 undetectable transcript least 2 year enrol . MR4.5 undetectable transcript must sustain 2 consecutive RQPCR assay within 6 month Patients diagnose AP BP CML Ph+ ALL Received cytotoxic chemotherapy TKIs except imatinib Any evidence ongoing graft versushost disease ( GVHD ) Relapsed patient allogeneic stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>